NCT04189848View on ClinicalTrials.gov

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

PHASE4CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

January 29, 2020

Study Completion Date

February 27, 2020

Conditions
Healthy VolunteersDiabetes Mellitus, Type 2OverweightObesity
Interventions
DRUG

Semaglutide

Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

DRUG

Dulaglutide

Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY